RaySearch Laboratories AB (publ) är glada att kunna meddela att Institut Curie i Frankrike, som har tre strålbehandlingscenter i Paris, Orsay och Saint-Cloud, har köpt dosplaneringssystemet RayStation®*. Institut Curie är en del av det franska sjukhusnätverket Unicancer och ordern är lagd inom ramen för Unicancers ramavtal 2019.
RayStation kommer främst att användas vid Institut Curie Proton Therapy Center i Orsay, som är ett av tre protoncenter i Frankrike, vilka alla nu kommer att vara utrustade med RayStation.
Köpet innebär att Institut Curie får tillgång till avancerad RayStation-teknologi såsom LET-optimering, adaptiv planering och AI-baserade funktioner för autokonturering för dosplanering med protoner och fotoner.
Régis Ferrand, Head of Physics, Institut Curie: “De avancerade nyckelverktyg som finns i RaySearchs system kommer att hjälpa oss att optimera kvaliteten på våra protonbehandlingar.”
Johan Löf, grundare och vd, RaySearch: “Vi är stolta över vårt samarbete med Institut Curie, som är ett välrenommerat sjukhus med en imponerande historia. Avtalet är ett första steg, men jag ser fram emot att fördjupa relationen för ett fortsatt givande samarbete.”
Det totala ordervärdet är cirka 1,7 MEUR exklusive serviceavtal, av vilket huvuddelen har intäktsredovisats under det tredje kvartalet 2024.
About Institut Curie
Institut Curie is France’s largest cancer research center and among the very best in Europe. It combines renowned research facilities with a cutting-edge hospital group to deliver excellence in clinical care. Institut Curie treats all types of cancers, even the rarest, and also serves as a Center of Excellence in Europe for breast cancer, as well as for pediatric cancers, eye tumors, and sarcomas. Founded in 1909 by Marie Curie, Institut Curie encompasses three sites (Paris, Saint-Cloud and Orsay) with more than 3,800 researchers, doctors, and caregivers, all sharing the common missions of research, excellence in clinical care, and sharing knowledge, to accelerate innovation in the fight against cancer and provide cutting-edge treatment to patients. For more information: institut-curie.org.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch's software has been sold to over 1,000 clinics in 44 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
Learn more about us on: